Eric Luthi Email & Phone Number

New York, NY, US

Springfield, New Jersey, US

Oversee all commercial aspects for launch of Evergreen products.

Allschwil, CH

Build, from scratch, the Canadian affiliate of Idorsia. First from Switzerland and then from Montreal, establish the legal entity, hire the executive leadership team, and lead the organizational development to launch the company’s first product. Responsible for the development of all aspects of country operations, including Medical Affairs, Public Policy.

Allschwil, CH

Following the demerger of Idorsia from Actelion post acquisition by JNJ, build the global marketing team for daridorexant (dual orexin antagonist for insomnia) and the commercial processes to operationalize the company’s first launch. Accountable to lead all global strategic marketing and cross-functional (access, medical, scientific, supply, insights).

Lead a diverse team of ~70 employees with responsibilities across customer engagement, business insights & analytics, patient support services, learning & development, compliance, and sales & marketing operations.

Managed Merck Canada’s portfolio of Primary Care (diabetes, respiratory) and Vaccine (HPV, Zoster, and a portfolio of tender-based pediatric vaccines) products

Full global P&L accountability and leader of commercialization efforts for BELSOMRA (suvorexant), the first-in-class orexin antagonist for the treatment of insomnia.

Led small team of commercial professionals responsible for working with the research and development teams to jointly develop the long-term CV franchise target strategy and to provide commercial input into the clinical development plans for products in phase 2 and beyond.

Hired as part of original team formed to develop Merck’s long-term strategic planning efforts.

Established commercialization plans for 2 pre-launch urinary bladder regeneration products for patients with neurogenic bladder and with invasive bladder cancer.